Safety and efficacy of biologics directed against TNF-α and CD20 in the therapy of vasculitis and systemic lupus erythematosus;Stellenwert von gegen TNF-α und CD20 gerichteten biologika in der therapie der vaskulitis und des systemischen lupus erythematodes

Therapeutische Umschau

Volumn 65, Issue 5, 2008, Pages 303-310

  Walker, Ulrich A ^a   Hasler, Paul ^b  

^a Rheumatologische Universitatsklinik und Poliklinik   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANCA ASSOCIATED VASCULITIS; BEHCET DISEASE; CHURG STRAUSS SYNDROME; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; GIANT CELL ARTERITIS; NONHUMAN; POLYARTERITIS NODOSA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 44349099704     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-930.65.5.303     Document Type: Review

References (42)

1. Savage CO, Harper L, Cockwell P, Adu D, Howie AJ. ABC of arterial and vascular disease: vasculitis. Bmj 2000 May 13; 320(7245): 1325-8.
2. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007 May 1; 146(9): 621-30.
3. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004 Jul; 50(7): 2296-304.
4. Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005 Jul; 32(7): 1371-3.
5. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007 Apr; 66(4): 565-6.
6. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007 May; 46(5): 736-41.
7. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004 Mar 2; 140(5): 404-6.
8. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005 Jan; 32(1): 98-105.
9. Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005 Sep 15; 106(6): 2050-8.
10. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006 Jan; 17(1): 160-9.
11. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006 Jan 15; 173(2): 180-7.
12. Flossmann O, Jones RB, Jayne DR, Luqmani RA. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 2006 Jul; 65(7): 841-4.
13. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006 Jul; 65(7): 853-8.
14. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002 Oct; 41(10): 1126-32.
15. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNF-alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004 Mar; 15(3): 717-21.
16. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005 Jan 27; 352(4): 351-61.
17. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006 May; 54(5): 1608-18.
18. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005 Nov 1; 143(9): 632-8.
19. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000 Sep; 27(9): 2172-8.
20. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003 May 15; 101(10): 3827-34.
21. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006 Jun; 33(6): 1197-8.
22. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007 Oct; 125(1): 30-3.
23. Hasler P, Zouali M. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin Ther Targets 2006 Dec; 10(6): 803-15.
24. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005 Sep; 17(5): 550-7.
25. Jonsdottir T, Gunnarsson I, Risselada A, Welin Henriksson E, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2007 Sep 24.
26. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 Aug; 50(8): 2580-9.
27. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006 Sep; 54(9): 2970-82.
28. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003 Apr; 62(4): 373-4.
29. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004 Sep; 15(5): 280-94.
30. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007 Jan-Feb; 25(1): 40-6.
31. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11; 345(15): 1098-104.
32. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003 May; 42(5): 617-21.
33. Strangfeld A, Listing J. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006 Dec; 20(6): 1181-95.
34. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 Nov; 52(11): 3403-12.
35. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006 Feb; 54(2): 628-34.
36. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007 Sep; 56(9): 2896-904.
37. Tubach F, Ravaud P, Salmon-Ceron D, Petitpain N, Brocq O, Grados F, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006 Nov 15; 43(10): e95-100.
38. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005 May; 64(5): 699-703.
39. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54(9): 2793-806.
40. Hainsworth JD. Safety of rituximab in the treatment of B-cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5 Suppl. 4: S12-6.
41. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007 Jul; 56(7): 2116-28.
42. Edwards JC, Cambridge G, Leandro MJ. B-cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006 Oct; 20(5): 915-28.